Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | WRN | Q14191 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CTRC | Q99895 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857906 | 0.81 | F2 (0.62) | BLMF2ELANECTSGCTRC | |
| SCHEMBL17962594 | 0.78 | BLM (0.50) | BLMWRNF2ELANECTSG | |
| SCHEMBL3678744 | 0.76 | F2 (0.43) | BLMF2ELANECTSGCTRC | |
| SCHEMBL11804614 | 0.75 | BLM (0.52) | BLMWRNALDH1A1MAPTKDM4E | |
| SCHEMBL3475268 | 0.74 | BLM (0.46) | BLMWRNALDH1A1MAPTNPSR1 | |
| SCHEMBL13578733 | 0.74 | F2 (0.42) | BLMWRNF2ELANECTSG | |
| SCHEMBL4685918 | 0.73 | NR1H2 (0.60) | ALDH1A1LMNAMAPTKDM4ECYP1B1 | |
| SCHEMBL14011308 | 0.73 | F2 (0.53) | BLMF2ELANECTSGCTRC | |
| SCHEMBL12235615 | 0.72 | LMNA (0.51) | BLMF2ELANECTSGCTRC | |
| SCHEMBL14468669 | 0.72 | ALDH1A1 (0.51) | BLMF2ELANECTSGCTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5139919-A | — | — | None | — | — | JP | disclosed |
| JP-57120502-A | — | — | None | — | — | JP | disclosed |
| EP-3915556-A1 | RECTAL APPLICATION OF THALIDOMIDE IN PATIENTS WITH HEMORRHAGIC CHRONIC RADIATION PROCTITIS | Vonnahme, Franz Josef (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2016119051-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | disclosed |
| EP-2699090-A1 | 3,4-DISUBSTITUTED PYRROLE 2,5-DIONES AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045689-A1 | 3,4-disubstituted pyrrole 2,5-diones and their use as fungicides | BASF SE (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2012143468-A1 | 3,4-DISUBSTITUTED PYRROLE 2,5-DIONES AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-8143283-B1 | Methods for treating blood-born tumors with thalidomide | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-7723361-B2 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide | CELGENE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1227111-A1 | TRIPHENYLBORON-CONTAINING POLYMERS AND USE THEREOF | Yoshitomi Fine Chemicals, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0877061-A1 | TRIPHENYLBORANE-ROSIN AMINE ADDUCT AND USE OF THE SAME | Yoshitomi Fine Chemicals, Ltd. (JP) | 1998-11-11 | — | — | EP | disclosed |
| JP-H05139919-A | UNDERWATER ANTIFOULING AGENT | YOSHITOMI PHARMACEUT IND LTD | 1993-06-08 | — | — | JP | disclosed |
| JP-S57120502-A | INSECTICIDE | MITSUBISHI CHEM IND LTD | 1982-07-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045689-A1 | 3,4-disubstituted pyrrole 2,5-diones and their use as fungicides | CYP51A1, DDT, DPM1 | BLM 4667/4885WRN 4589/4885F2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.